S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:GNCA

Genocea Biosciences (GNCA) Stock Forecast, Price & News

$0.0002
0.00 (0.00%)
(As of 09/27/2023 ET)
Compare
Today's Range
$0.0002
$0.0002
50-Day Range
N/A
52-Week Range
$0.0001
$0.0001
Volume
645 shs
Average Volume
83,499 shs
Market Capitalization
$11,746.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

GNCA stock logo

About Genocea Biosciences (NASDAQ:GNCA) Stock

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

GNCA Price History

GNCA Stock News Headlines

GNCAQ Genocea Biosciences, Inc.
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Genocea Biosciences, Inc. (GNCA)
GRPN, GNCA and LAB among mid-day movers
Genocea Biosciences to shut down
Genocea Closes Shop, Delists From NASDAQ
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Genocea cuts two-thirds of staff, explores a sale
Genocea Biosciences to Host Investor Webinar
Genocea Biosciences: Q4 Earnings Snapshot
Genocea Provides Fourth Quarter 2021 Corporate Update
Genocea Biosciences Q4 2021 Earnings Preview
Genocea Biosciences Earnings Preview
See More Headlines
Receive GNCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter.

GNCA Company Calendar

Last Earnings
10/27/2021
Today
9/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GNCA
Employees
74
Year Founded
N/A

Profitability

Net Income
$-33,200,000.00
Pretax Margin
-1,946.15%

Debt

Sales & Book Value

Annual Sales
$1.91 million
Book Value
$0.47 per share

Miscellaneous

Free Float
57,788,000
Market Cap
$11,746.00
Optionable
Optionable
Beta
1.61
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. William D. Clark M.B.A. (Age 53)
    Pres, CEO & Director
    Comp: $837.42k
  • Dr. Jessica Baker Flechtner Ph.D. (Age 50)
    Chief Scientific Officer
    Comp: $585.18k
  • Ms. Diantha Duvall CPA (Age 50)
    M.B.A., CFO & Sec.













GNCA Stock - Frequently Asked Questions

How have GNCA shares performed in 2023?

Genocea Biosciences' stock was trading at $0.0002 at the start of the year. Since then, GNCA shares have increased by 0.0% and is now trading at $0.0002.
View the best growth stocks for 2023 here
.

How were Genocea Biosciences' earnings last quarter?

Genocea Biosciences, Inc. (NASDAQ:GNCA) posted its quarterly earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.15. The biotechnology company had revenue of $1.64 million for the quarter. During the same quarter in the previous year, the firm posted ($0.26) EPS.

What is William Clark's approval rating as Genocea Biosciences' CEO?

5 employees have rated Genocea Biosciences Chief Executive Officer William Clark on Glassdoor.com. William Clark has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Genocea Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Hudson Technologies (HDSN), Accenture (ACN) and AutoZone (AZO).

What is Genocea Biosciences' stock symbol?

Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA."

How do I buy shares of Genocea Biosciences?

Shares of GNCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genocea Biosciences' stock price today?

One share of GNCA stock can currently be purchased for approximately $0.00.

How much money does Genocea Biosciences make?

Genocea Biosciences (NASDAQ:GNCA) has a market capitalization of $11,746.00 and generates $1.91 million in revenue each year. The biotechnology company earns $-33,200,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

How can I contact Genocea Biosciences?

Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The official website for the company is www.genocea.com. The biotechnology company can be reached via phone at (617) 876-8191, via email at ir@genocea.com, or via fax at 617-876-8192.

This page (NASDAQ:GNCA) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -